Skip to main content
Premium Trial:

Request an Annual Quote

Roche Cobas Assays Get Additional CE Claims for Organ, Tissue Testing

NEW YORK (GenomeWeb) — Roche said today that its Cobas MPX and Cobas WNV assays can now be used for testing of human organ and tissue from cadaveric donors, thus expanding the range of approved uses for the Cobas 6600/8800 systems in markets recognizing CE marking.

The new claims allow for pre-transplantation testing of organ and tissue donations to protect transplant recipients from the donation-related transmission of HIV, hepatitis B virus, hepatitis C virus, and West Nile virus.

In the EU, organ transplantation from deceased donors is performed for more than 30,000 patients annually, Roche said. The urgent nature of organ transplant requires infectious disease screening to be carried out as quickly as possible.

Cobas MPX is a real-time PCR multiplex assay that covers five targets — HIV-1 Group M, HIV-1 Group O, HIV-2, HCV, and HBV — from a single sample. Cobas WNV is a real-time PCR test for West Nile virus that is highly sensitive for both WNV lineages 1 and 2. It also provides broad coverage of other flaviviruses that can cause transfusion-transmitted infections.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.